Innovation > Odak Project
Innovation & SIFI
From the very beginning we believed we could help people see, and still today trust in that 20/20 perfect vision.

ODAK is a European FP7 project for the pharmaceutical development of an orphan drug for the rare ocular disease Acanthamoeba Keratitis.


Project Summary
Orphan Drug for Acanthamoeba Keratitis (ODAK)

ODAK is a research project to develop the Orphan Drug Polihexanide (PHMB) to provide a safe and effective drug for the treatment of Acanthamoeba keratitis. This is an infectious disease caused by a free living microorganism called Acanthamoeba, present in air, soil and water. The microorganism can infect eyes and is often linked to contact lens wearing, especially when poor eye-care is a factor.

Without treatment, this debilitating  eye disease causes patients to suffer severe pain, vision loss and eye enucleation.  Currently, there is no approved drug to treat this infectious rare disease. To improve this situation and provide an approved drug treatment, the ODAK project has been set-up. Led by SIFI SpA, an Italian company specialising in eye care products, the project is co-funded by the European Commission FP7 programme.

The ODAK project will undertake scientific research using laboratory experiments and clinical studies with patients, to provide scientific evidence to support the development of the first approved drug targeting Acanthamoeba keratitis. In addition the project will provide information and advice to doctors and healthcare providers on how to treat patients effectively.

Our research programme is expected to identify and test new PHMB formulations to find the most effective drug therapy for treating patients.

continue reading on the ODAK orphan drug for Acanthamoeba Keratitis website

Patient information guide
For a better knowledge of this serious disease and of its effects, patients suffering from Acanthamoeba Keratitis, their relatives, their friends and anybody providing care for them, can read the Patient information guide provided by Moorfields Eye Hospital.

share & tag us with
#history #EyeCare #eyeinfo #health #innovation #business #eye #vision #leadership #pharma


"The best vision is insight."
Malcolm Forbes
Important Dates in Vision Science! share & tag us with #history #EyeCare #eyeinfo #health #innovation #DidYouKnow #eye #vision #leadership #pharma
  SIFI SOUND MEDSTM SIFI announces Sound MedsTM, a new audio technology that speaks to patients! Sound MedsTM  helps patients better comprehend drug illustration...
To celebrate its 80th anniversary, in 2015, SIFI has decided to support socially noteworthy innovations, intended to improve the quality of life of individuals with...

On our Social Channels

From our News Center

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today...


20 September

As of today Fabrizio Folco assumes management of the company's organization for the Italian market SIFI, Italian leader in the development and marketing of innovative...
Follow Us!